Over the last few days, attendees of the ongoing annual meeting of the Alzheimer’s Association have been arriving in Amsterdam for what has turned out to be a p 18 July 2023
While targeted protein-busting antibodies are revolutionizing the treatment of Alzheimer’s disease, a damaging side effect - amyloid-related imaging abnormaliti 17 July 2023
At the AAIC in Amsterdam, we’re speaking with two key figures from Lilly's development program for donanemab, as the company presents new data that could help i 17 July 2023
In Alzheimer's, most of the focus has been on the newly-emerging class of intravenous biologics for early-stage disease, and the potential for subcutaneous vers 17 July 2023
The recent full approval of Leqembi (lecanemab-irmb) has upped the stakes for what promises to be a particularly intriguing congress of the Alzheimer’s Associat 12 July 2023
Eisai has broken new ground in the development of Alzheimer's treatments, gaining the first approval for decades. In the runup to AAIC 2023, we discuss progress 6 July 2023
The anti-amyloid beta (Aβ) protofibril antibody lecanemab is not just a potentially crucial medicine for Alzheimer’s patients and for drug companies Eisai, Biog 5 August 2022
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.